Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: A cohort study

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 11, 2011, Pages 2573-2578

  Broeders, Nilufer E ^a   Hombrouck, Anneleen ^a   Lemy, Anne ^b   Wissing, Karl Martin ^c   Racapé, Judith ^b   Gastaldello, Karine ^b   Massart, Annick ^b   van Gucht, Steven ^a   Weichselbaum, Laura ^b   de Mul, Aurelie ^b   Brochier, Bernard ^a   Thomas, Isabelle ^a   Abramowicz, Daniel ^b  

^a ERASME HOSPITAL   (Belgium)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIALYSIS; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; RENAL REPLACEMENT THERAPY; SEROCONVERSION; VACCINATION;

ADULT; AGED; ALPHA-TOCOPHEROL; ANALYSIS OF VARIANCE; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BELGIUM; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; POLYSORBATES; REGRESSION ANALYSIS; RENAL DIALYSIS; SQUALENE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80655131166     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04670511     Document Type: Article

References (35)

1. Kumar D, Morris MI, Kotton CN, Fischer SA, Michaels MG, Allen U, Blumberg EA, Green M, Humar A, Ison MG: Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 10: 18-25, 2010
2. Avery RK, Michaels M: Update on immunizations in solid organ transplant recipients: What clinicians need to know. Am J Transplant 8: 9-14, 2008
3. 2009 pandemic influenza A (H1N1) virus infections-Chicago, Illinois, April-July 2009. MMWR Morb Mortal Wkly Rep 58: 913-918, 2009
4. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM: Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361: 1945-1952, 2009
5. Use of influenza A (H1N1) 2009 monovalent vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 58: 1-8, 2009
6. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson L: Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361: 2424-2435, 2009
7. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL: Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361: 2405-2413, 2009
8. Candon S, Thervet E, Lebon P, Suberbielle C, Zuber J, Lima C, Charron D, Legendre C, Chatenoud L: Humoral and cellu-lar immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 9: 2346-2354, 2009
9. Scharpe J, Evenepoel P, Maes B, Bammens B, Claes K, Osterhaus AD, Vanrenterghem Y, Peetermans WE: Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 8: 332-337, 2008
10. Birdwell KA, Ikizler MR, Sannella EC, Wang L, Byrne DW, Ikizler TA, Wright PF: Decreased antibody response to influenza vaccination in kidney transplant recipients: A prospective cohort study. Am J Kidney Dis 54: 112-121, 2009
11. Salles MJ, Sens YA, Boas LS, Machado CM: Influenza virus vaccination in kidney transplant recipients: Serum antibody response to different immunosuppressive drugs. Clin Trans-plant 24: E17-E23, 2010
12. Song JY, Cheong HJ, Ha SH, Kee SY, Jeong HW, Kim WJ: Active influenza immunization in hemodialysis patients: Comparison between single-dose and booster vaccination. Am J Nephrol 26: 206-211, 2006
13. Société de Néphrologie. Grippe A (H1N1): Propositions de recommendations pour les patients transplantés. ICAR, editor. 12-10-2009. http://www.soc-nephrologie.org/PDF/enephro/recommandations/grippe/SN_SFD_SFT.pdf
14. Lemy A, Andrien M, Wissing KM, Ryhahi K, Vandersarren A, Racape J, Heylen C, Ghisdal L, Broeders E, Vereerstraeten P, Toungouz M, Abramowicz D: Major histocompatibility com-plex class 1 chain-related antigen a antibodies: Sensitizing events and impact on renal graft outcomes. Transplantation 90: 168-174, 2010
15. Zou Y, Stastny P, Susal C, Dohler B, Opelz G: Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 357: 1293-1300, 2007
16. Terasaki PI, Ozawa M, Castro R: Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 7: 408-415, 2007
17. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garcon N, Van Mechelen M: Adjuvant system AS3 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29: 2461-2473, 2011
18. Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L: Dose-Sparing H5N1 A/Indonesia/05/ 2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A phase III, placebo-controlled, randomized study. J Infect Dis 203: 1729-1738, 2011
19. Mizutani K, Terasaki P, Rosen A, Esquenazi V, Miller J, Shih RN, Pei R, Ozawa M, Lee J: Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 5: 2265-2272, 2005
20. Lee PC, Zhu L, Terasaki PI, Everly MJ: HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 88: 568-574, 2009
21. Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, Pratschke J, Rudolph B, Schmidt D, Salama A, Schonemann C: Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplanta-tion 87: 1505-1513, 2009
22. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz J: Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37: 937-943, 1999
23. Perkins FT: A ready reckoner for the calculation of geometric mean antibody titres. J Gen Microbiol 19: 540-541, 1958
24. Horne AD: The statistical analysis of immunogenicity data in vaccine trials. Ann N Y Acad Sciences 754: 329-346, 1995
25. The European Agency for the evaluation of Medicinal Products (EMEA) and committee for proprietary medicinal products (CPMP): Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96; 12 March 1997 http://www.emea.eu.int/pdfs/human/bwp/021496en.pdf, 2007
26. Smith KG, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG: Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 13: 160-164, 1998
27. Sanchez-Fructuoso AI, Prats D, Naranjo P, Fernandez-Perez C, Gonzalez MJ, Mariano A, Gonzalez J, Figueredo MA, Martin JM, Paniagua V, Fereres J, Gomez Concha E., Barrientos A: Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug ther-apy immunosuppression protocols: Mycophenolate versus azathioprine. Transplantation 69: 436-439, 2000
28. Scharpe J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, Claes K, Osterhaus AD, Vanrenterghem Y, Evene-poel P: Immunogenicity of a standard trivalent influenza vac-cine in patients on long-term hemodialysis: An open-label trial. Am J Kidney Dis 54: 77-85, 2009
29. ®) in renal transplant recipients. Nephrol Dial Trans-plant 2011, first published online May 25, 2011.doi:10.1093/ndt/gfr 278 in press
30. Esposito S, Meregalli E, Daleno C, Ghio L, Tagliabue C, Valzano A, Serra D, Galeone C, Edefonti A, Principi N: Anopen-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vac-cine to paediatric kidney transplant recipients. Nephrol Dial Transplant 26: 2018-2024, 2011
31. Labriola L, Hombrouck A, Marechal C, Van GS, Brochier B, Thomas I, Jadoul M, Goubau P: Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in hae-modialysed patients. Nephrol Dial Transplant 26: 1424-1428, 2011
32. Dikow R, Eckerle I, Ksoll-Rudek D, Hampel H, Schwenger V, Zeier M, Schnitzler P, Sommerer C: Immunogenicity and efficacy in haemodialysis patients of an AS03(A)-adjuvanted vac-cine for 2009 pandemic influenza A (H1N1): A nonrandom-ized trail. Am J Kidney Dis 57: 716-723, 2011
33. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant. 4[Suppl 10]: 160-163, 2004
34. Danziger-Isakov L, Cherkassky L, Siegel H, McManamon M, Kramer K, Budev M, Sawinski D, Augustine JJ, Hricik DE, Fairchild R, Heeger PS, Poggio ED: Effects of influenza immu-nization on humoral and cellular alloreactivity in humans. Transplantation 89: 838-844, 2010
35. Blumberg EA, Albano C, Pruett T, Isaacs R, Fitzpatrick J, Bergin J, Crump C, Hayden FG: The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 22: 295-302, 1996